IPH4502 is a novel and differentiated topoisomerase I inhibitor ADC designed to precisely target Nectin-4, a cell adhesion ...

An MRI instead of a surgical procedure helped speed up the wait between diagnosis and treatment, UK research has found ...

Dr. Balazs Halmos discusses the significance of the approval of subcutaneous Opdivo and what this treatment formulation means ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

BladderPath trial found that patients with suspected invasive bladder cancer undergoing initial mpMRI were treated faster ...

Patients with a common aggressive type of bladder cancer could get correct treatment significantly quicker as new research ...

A KEIGHLEY deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

Shanghai Junshi Biosciences Co., Ltd (Junshi Biosciences, HKEX: 1877; SSE: 688180), a leading innovation-driven biopharmaceutical company dedicated to the discovery ...

A Keighley deli owner is taking part in clinical trials of a new drug which could transform bladder cancer treatment.

ALX Oncology Holdings Inc. (NASDAQ:ALXO – Get Free Report) has earned a consensus recommendation of “Moderate Buy” from the six analysts that are presently covering the firm, Marketbeat.com reports.

Executing in oncology with investigational BNT327/PM8002 combinations and mRNA cancer immunotherapy candidates as pan-tumor treatment approaches ...